Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal Abuse Potential of Oxycodone IR ADF
NCT03765346Phase 1Completed
- Sponsor
- Grünenthal GmbH
- Start
- Jul 2018
- Primary completion
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of oxycodone in pain (3 arms), sponsored by Grünenthal GmbH. Primary endpoint: Peak effect (Emax) for Drug Liking at 24 hours. Started Jul 2018; status: completed.
02
Drugs
oxycodone
03
Conditions
pain
Beyond the preview
Go deeper on NCT03765346.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03765346.